Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Tri-Ax
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Halberd Corp’s TBI Nasal Spray Shows Promising Phase II Test Results
Details : Halberd's Tri-Ax™ is a nasal spray aimed at mitigating traumatic brain injury (TBI). It shows promising Phase II results, improving motor function after head trauma.
Brand Name : Tri-Ax
Molecule Type : Undisclosed
Upfront Cash : Not Applicable
July 24, 2024
Lead Product(s) : Tri-Ax
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Partnership
Halberd Corporation Plans to Extend Research Partnership with Mississippi State University
Details : Under the agreement, the testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
November 15, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Agreement
Details : Under the agreement, the testing will focus on Halberd's patent-pending nasal spray designed to mitigate the effects of Traumatic Brain Injury (TBI), when administered shortly after sustaining head trauma.
Brand Name : Undisclosed
Molecule Type : Undisclosed
Upfront Cash : Undisclosed
March 30, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Preclinical
Sponsor : Mississippi State University
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Study Phase : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
Halberd Signs Development and Marketing Agreement for Medications & Nutraceuticals
Details : Under this agreement, Hamden will have worldwide exclusive rights to sell, market and distribute the HALB patented low-dose Naltrexone medication, and the HALB proprietary Vita-Shield-Max TM Nutraceutical Product.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
November 14, 2022
Lead Product(s) : Naltrexone Hydrochloride
Therapeutic Area : Neurology
Highest Development Status : Undisclosed
Sponsor : Hamden Group
Deal Size : Undisclosed
Deal Type : Agreement
LOOKING FOR A SUPPLIER?